[logo] HealthTree Foundation
search person

Clinical Trial: Evaluating the Safety and Efficacy of KITE-585 in Subjects With Relapsed/Refractory Multiple Myeloma

Posted: Jun 29, 2018
Clinical Trial: Evaluating the Safety and Efficacy of KITE-585 in Subjects With Relapsed/Refractory Multiple Myeloma image

A Phase I study is open evaluating the safety of a CAR T-cell treatment called KITE-585 for patients with relapsed/refractory myeloma.

KITE-585 is an autologous engineered CAR T-cell product targeting a protein commonly found on myeloma cells called BCMA. Patients eligible for this trial will have their white blood cells collected via apheresis, and these cells are then genetically modified to make KITE-585.

Patients will receive a 3 day conditioning course of chemotherapy, consisting of fludarabine and cyclophosphamide, followed by a single dose infusion of KITE-585.

This trial is seeking an estimated 64 participants, and will be testing dose escalation and assessing overall response, duration of response, incidence of adverse effects, and duration of progression free survival. This trial is currently recruiting patients at multiple locations in the US.

Patients must have relapsed/refractory myeloma, and adequate bone marrow, renal, hepatic, pulmonary, and cardiac function.

Click the button below to learn more about this study and see if you are eligible. You can also call SparkCures with any questions at (888) 828-2206.

Study of Safety and Efficacy of KITE-585

A Phase I study is open evaluating the safety of a CAR T-cell treatment called KITE-585 for patients with relapsed/refractory myeloma.

KITE-585 is an autologous engineered CAR T-cell product targeting a protein commonly found on myeloma cells called BCMA. Patients eligible for this trial will have their white blood cells collected via apheresis, and these cells are then genetically modified to make KITE-585.

Patients will receive a 3 day conditioning course of chemotherapy, consisting of fludarabine and cyclophosphamide, followed by a single dose infusion of KITE-585.

This trial is seeking an estimated 64 participants, and will be testing dose escalation and assessing overall response, duration of response, incidence of adverse effects, and duration of progression free survival. This trial is currently recruiting patients at multiple locations in the US.

Patients must have relapsed/refractory myeloma, and adequate bone marrow, renal, hepatic, pulmonary, and cardiac function.

Click the button below to learn more about this study and see if you are eligible. You can also call SparkCures with any questions at (888) 828-2206.

Study of Safety and Efficacy of KITE-585

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can contribute to cures by joining HealthTree Cure Hub and joining clinical research. Founder and CEO of HealthTree Foundation. 

Thanks to our sponsors:
Sanofi logo
Adaptive logo
Pfizer logo
GSK logo
newsletter icon

Get the Latest Multiple Myeloma Updates, Delivered to You.

By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.